Latest Beta-lactam antibiotics Stories
EU5 Payers Indicate that Tightening Budgets Mean Emerging Brands Must Demonstrate Compelling Cost-Effectiveness Over Current Therapies in Order to Justify Reimbursement at a Premium Price, According to a New Report from Decision Resources BURLINGTON, Mass., June 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed physicians from the EU5 (France, Germany,...
WESTON, FL, May 10, 2013 /PRNewswire/ - Apotex Corp. announced today that it is conducting, on behalf of the manufacturer Hospira, Inc., a voluntary nationwide recall of 21 lots of Piperacillin and Tazobactam for Injection, USP 40.5 grams, NDC number 60505-0773-00 to the hospital / healthcare provider /user level. The impacted lots of Piperacillin and Tazobactam for Injection, USP 40.5 grams may show precipitation / crystallization in IV bag or IV line after reconstitution....
WESTON, FL, April 26, 2013 /PRNewswire/ - Apotex Corp. announced today that it is conducting, on behalf of the manufacturer Hospira, Inc., a voluntary nationwide recall of 15 lots of Piperacillin and Tazobactam for Injection, USP 40.5 grams, NDC number 60505-0773-00 to the hospital / healthcare provider /user level. The impacted lots of Piperacillin and Tazobactam for Injection, USP 40.5 grams may show precipitation / crystallization in IV bag or IV line after reconstitution....
Eravacycline's Competitive Advantages Include Activity Against Multidrug-Resistant Pathogens and Availability in Interchangeable IV and Oral Formulations, According to a New Report from Decision Resources BURLINGTON, Mass., April 24, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought leaders, Tetraphase Pharmaceuticals'...
ST. PETERSBURG, Fla., April 9, 2013 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announced in-vitro study results suggesting ACTICOAT Silver-Coated Antimicrobial Dressings are bactericidal against some antibiotic resistant organisms carrying the NDM-1 enzyme, often referred to as 'superbugs'. An in-vitro laboratory study showed ACTICOAT Dressings, containing patented Nanocrystalline Silver technology, can kill the antibiotic...
A year-old report from the New England Journal of Medicine has prompted the U.S. Food and Drug Administration to warn doctors and patients about sharply increased heart risks when taking the popular antibiotic azithromycin, more commonly known as Zithromax or Z-Pak. In Philadelphia, personal injury attorney Richard P. Console Jr. wonders what this new federal alert could mean for patients who’ve already suffered a severe reaction to Zithromax. Marlton, NJ (PRWEB) March 22, 2013 A...
redOrbit Staff & Wire Reports - Your Universe Online Not only is the antibiotic amoxicillin ineffective in treating coughs not linked to pneumonia, but it could actually be harmful if taken in some instances, a team of European researchers warns in a new study. "Using the antibiotic amoxicillin to treat respiratory infections in patients not suspected of having pneumonia is not likely to help and could be harmful," University of Southampton professor Paul Little told BBC News on...
ROCKVILLE, Md., Nov. 12, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the Company has entered into an agreement with Prev AbR LLC to acquire its clinical-stage and related beta-lactamase assets targeted for the prevention of Clostridium difficile (C. diff) infection, the leading cause of hospital acquired infections (HAI), that may occur secondary...
BALTIMORE, Sept. 27, 2012 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), today announced the release of a research use only (RUO) molecular test designed to rapidly detect antibiotic resistance genes found in the superbug known as carbapenem-resistant Enterobacteriaceae (CRE). These deadly organisms are associated with high mortality rates, are easily spread from patient-to-patient and are resistant to nearly all antibiotics. In some...
SAN DIEGO, Sept. 7, 2012 /PRNewswire/ -- Rempex Pharmaceuticals, Inc. today announced that it will present data describing the antimicrobial activity and preclinical safety of Carbavance(TM), a broad-spectrum antibiotic combination agent designed to treat serious bacterial infections due to Gram-negative bacteria. Preclinical studies show that Carbavance has activity against key Gram-negative pathogens, including E. coli, Klebsiella sp., Acinetobacter sp., and Pseudomonas...
